Clinical Trials
33 trialsNCT03975829 2026-06-02
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Phase 4 Recruiting
NCT02381886 2026-04-13
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Novartis
Phase 1 Active not recruiting
NCT05484622 2026-03-12
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
Servier
Phase 1 Active not recruiting
NCT05303519 2026-03-05
SIGMA
Nuvation Bio Inc.
Phase 3 Recruiting
NCT05267106 2025-12-30
FIGHT-209
Incyte Corporation
Phase 2 Terminated
NCT04541082 2025-12-18
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Jazz Pharmaceuticals
Phase 1 Recruiting
NCT05737212 2025-02-21
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
Phase 1/2 Terminated
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting
NCT05561374 2024-11-29
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato, Inc.
Phase 1 Active not recruiting
NCT03043391 2024-04-08
Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children
Istari Oncology, Inc.
Phase 1 Completed
NCT02684058 2023-12-13
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors
Novartis
Phase 2 Completed
NCT01986348 2023-01-26
KING
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT03649464 2022-10-07
Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants
Oblato, Inc.
Phase 1/2 Withdrawn
NCT02871843 2022-05-16
G-FORCE-1
EpicentRx, Inc.
Phase 1 Completed
NCT04327011 2020-03-30
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Tocagen Inc.
Phase 1 Terminated
NCT02764151 2020-01-27
First in Patient Study for PF-06840003 in Malignant Gliomas
Pfizer
Phase 1 Terminated
NCT01156584 2018-05-21
A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma
Tocagen Inc.
Phase 1 Completed
NCT01470794 2018-05-21
Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor
Tocagen Inc.
Phase 1 Completed
NCT01985256 2018-05-21
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Tocagen Inc.
Phase 1 Completed
NCT00392171 2017-06-07
The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00539344 2014-07-31
A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma
Angiochem Inc
Phase 1 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00006368 2013-05-01
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
Phase 1 Completed
NCT01656980 2012-08-03
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase 3 Unknown
NCT01637753 2012-07-11
Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase NA Unknown
NCT00004212 2012-05-16
DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Phase 1 Completed
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00064779 2011-06-06
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00062504 2011-05-23
Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated
NCT00591058 2009-07-17
Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma
TransMolecular
Phase 1 Unknown
NCT00683761 2009-07-17
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
TransMolecular
Phase 1/2 Unknown
NCT00080054 2009-04-03
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
Pharmacyclics LLC.
Phase 1 Completed
NCT00743353 2009-02-02
K5
Siemens Molecular Imaging
Phase EARLY_PHASE1 Completed